🇺🇸 FDA
Patent

US 8933111

Crystalline form of (2S,4R)-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-4-[(1H-[1,2,3]triazole-4-carbonyl)-amino]-pentanoic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester

granted A61KA61K31/4192A61K45/06

Quick answer

US patent 8933111 (Crystalline form of (2S,4R)-5-biphenyl-4-yl-2-hydroxymethyl-2-methyl-4-[(1H-[1,2,3]triazole-4-carbonyl)-amino]-pentanoic acid 5-methyl-2-oxo-[1,3]dioxol-4-ylmethyl ester) held by Theravance Biopharma R&D IP, LLC expires Mon Jan 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Jan 13 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 08 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
14
CPC classes
A61K, A61K31/4192, A61K45/06, A61P, A61P13/12